Literature DB >> 12616194

Management of cholesteatoma: status of the canal wall.

Mark J Syms1, William M Luxford.   

Abstract

OBJECTIVE/HYPOTHESIS: Management of chronic otitis media with cholesteatoma remains controversial. The purpose of the study is to examine factors associated with the surgical approach to manage cholesteatoma. STUDY
DESIGN: A retrospective review.
METHODS: A retrospective review was made of all primary cases of mastoid surgery for cholesteatoma performed at an otological center between 1995 and 2000. During the study period, 486 ears underwent surgery for cholesteatoma. Data included procedures performed, location and extent of the disease, residual and recurrent disease, complications, reasons for staging the surgery, and duration of follow-up.
RESULTS: The canal wall remained intact in 68.5% of ears. The majority of the remainder of the patients underwent a canal wall down technique with mastoid obliteration. Residual cholesteatoma was found in 26.9% of second procedures and in 2.7% of third procedures.
CONCLUSIONS: The majority of patients with cholesteatoma can be adequately managed with a canal intact tympanomastoidectomy with staging. Otolaryngologists should consider a two-staged procedure as a viable management approach for chronic otitis media with cholesteatoma.

Entities:  

Mesh:

Year:  2003        PMID: 12616194     DOI: 10.1097/00005537-200303000-00010

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  13 in total

Review 1.  Imaging of the postoperative middle ear.

Authors:  Marc T Williams; Denis Ayache
Journal:  Eur Radiol       Date:  2004-01-29       Impact factor: 5.315

2.  Diffusion-weighted magnetic resonance imaging in the management of cholesteatoma.

Authors:  Mudit Jindal; Jayesh Doshi; Manoj Srivastav; David Wilcock; Richard Irving; Ranit De
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-07-04       Impact factor: 2.503

3.  Dealing with paediatric cholesteatoma: how we changed our management.

Authors:  B Sergi; J Galli; M Battista; E De Corso; G Paludetti
Journal:  Acta Otorhinolaryngol Ital       Date:  2014-04       Impact factor: 2.124

4.  Through the Eustachian Tube and Beyond: A New Miniature Robotic Endoscope to See Into The Middle Ear.

Authors:  Loris Fichera; Neal P Dillon; Dongqing Zhang; Isuru S Godage; Michael A Siebold; Bryan I Hartley; Jack H Noble; Paul T Russell; Robert F Labadie; Robert J Webster
Journal:  IEEE Robot Autom Lett       Date:  2017-02-14

5.  Cochlear implantation and management of chronic suppurative otitis media: single stage procedure?

Authors:  S Basavaraj; M Shanks; N Sivaji; Agnes A Allen
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-03-09       Impact factor: 2.503

6.  Outcomes of Using Otoendoscopy During Surgery for Cholesteatoma.

Authors:  Alaa Eldin M Elfeky; Alaa O Khazbzk; Wail F Nasr; Tarek A Emara; Mohamed W Elanwar; Hazem S Amer; Yasser A Fouad
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2017-02-06

7.  Canal wall reconstruction in cholesteatoma surgeries: rate of residual.

Authors:  A Roux; D Bakhos; E Lescanne; J-P Cottier; A Robier
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-09-17       Impact factor: 2.503

8.  Surgical results of retrograde mastoidectomy with primary reconstruction of the ear canal and mastoid cavity.

Authors:  Chao-Yin Kuo; Bor-Rong Huang; Hsin-Chien Chen; Cheng-Ping Shih; Wei-Kang Chang; Yang-Lien Tsai; Yuan-Yung Lin; Wan-Chun Tsai; Chih-Hung Wang
Journal:  Biomed Res Int       Date:  2015-03-15       Impact factor: 3.411

9.  Cochlear implantation in patients with chronic otitis media: 7 years' experience in Maastricht.

Authors:  Job T F Postelmans; Robert J Stokroos; Joris J Linmans; Bernd Kremer
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-11-04       Impact factor: 2.503

Review 10.  Results of endoscopic middle ear surgery for cholesteatoma treatment: a systematic review.

Authors:  L Presutti; F M Gioacchini; M Alicandri-Ciufelli; D Villari; D Marchioni
Journal:  Acta Otorhinolaryngol Ital       Date:  2014-06       Impact factor: 2.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.